Greenwich Lifesciences EBITDA vs. Cash Flow from Operations

GLSI
 Stock
  

USD 9.10  0.37  3.91%   

For Greenwich Lifesciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Greenwich Lifesciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Greenwich Lifesciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Greenwich Lifesciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Greenwich Lifesciences over time as well as its relative position and ranking within its peers. Please check Risk vs Return Analysis.
  
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Greenwich Lifesciences Cash Flow from Operations vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Greenwich Lifesciences's current stock value. Our valuation model uses many indicators to compare Greenwich Lifesciences value to that of its competitors to determine the firm's financial worth.
Greenwich Lifesciences is one of the top stocks in ebitda category among related companies. It is one of the top stocks in cash flow from operations category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Greenwich Lifesciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Greenwich Lifesciences' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Greenwich Lifesciences' earnings, one of the primary drivers of an investment's value.

Greenwich Cash Flow from Operations vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Greenwich Lifesciences 
EBITDA 
 = 
Revenue 
-  
Basic Expenses 
(5.98 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Greenwich Lifesciences 
Operating Cash Flow 
 = 
EBITDA 
-  
Taxes 
(5.71 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Greenwich Lifesciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Greenwich Lifesciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Greenwich Lifesciences will eventually generate negative long term returns. The profitability progress is the general direction of Greenwich Lifesciences' change in net profit over the period of time. It can combine multiple indicators of Greenwich Lifesciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Greenwich Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Greenwich Lifesciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Greenwich Lifesciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Greenwich Lifesciences' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fund Screener Now

   

Fund Screener

Find actively-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Module

Use Investing Themes to Complement your Greenwich Lifesciences position

In addition to having Greenwich Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Entertainment Thematic Idea Now

Entertainment
Entertainment Theme
Companies from entertainment industry including show business, news and media. The Entertainment theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
View All  Next Launch
Please check Risk vs Return Analysis. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
To fully project Greenwich Lifesciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Greenwich Lifesciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Greenwich Lifesciences' income statement, its balance sheet, and the statement of cash flows.
Potential Greenwich Lifesciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Greenwich Lifesciences investors may work on each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.